

Appendix 4E

Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent
company reference

25 006 194 752

Financial year ended
(‘current period’)

30 June 2017

Financial year ended
(‘previous period’)

30 June 2016

2. Results for announcement to the market

ASX Listing Rules Ref		2017 A\$'000	2016 A\$'000	% change
2.1	Revenue from continuing operations	31,619	27,577	14.7%
2.2	Underlying Profit after Tax (minus currency gains/(losses))	9,865	6,431	53.4%
	Currency gains/(losses) after tax	(544)	(63)	N/A
	Profit/(Loss) from ordinary activities after tax attributable to members	9,321	6,368	46.4%
2.3	Net Profit/(Loss) for the period attributable to members	9,321		
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.	Up 46.4%		

2.4	Dividends (distributions)	Amount per security	Franked/Unfranked amount per security
	Dividend amount per security		
	Final Dividend (franked)	2.5 cents	2.5 cents
	Interim dividend (unfranked)	1.5 cents	1.5 cents
2.5	Record date for Final dividends	8 September 2017	
	Payment date for Final dividends	28 September 2017	

<p>2.6</p>	<p><u>Australia</u></p> <p>The Group's Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.</p> <p>The Group's Australian revenue was 28.6% above last year as a result of new sales of both the Visage PACS and Visage RIS products with a number of sales being for the combined product offering.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its market position despite increasing competition.</p> <p><u>North America</u></p> <p>The growing North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 27.6% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream.</p> <p><u>Europe</u></p> <p>The Group's employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations decreased by 58.2% from last year, due to a large capital sale to a German government hospital in the prior year</p> <p><u>Financials</u></p> <p>Reported profit after tax for the period was \$9.32m an increase of \$2.95m (46.4%) from the previous year.</p> <p>Full year revenue of the Group increased from \$27.58m to \$31.62m, an increase of 14.7%.</p> <p>The key drivers of the profit increase was the significant increase in the performance of the North American and Australian operations.</p> <p>As the Group's costs are relatively fixed, an increase in sales has a significant impact on profitability.</p> <p>As a result, it is anticipated that the 2018 financial year will show a continuing improvement in operational results, however this is dependent upon many market factors over which the Directors have limited or no control.</p> <p><u>Shareholder Returns</u></p> <p>The directors are confident that the holdings of reserve cash are sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.</p>
<p>3.</p>	<p>Statement of Comprehensive Income</p> <p>Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p>4.</p>	<p>Statement of Financial Position</p> <p>Please refer to the Statement of Financial Position in the attached Financial Statements.</p>
<p>5.</p>	<p>Statement of cash flows</p> <p>Please refer to the Statement of cash flows in the attached Financial Statements.</p>

6.	<p>Details of Dividends</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2017 \$'000</th> <th style="text-align: right; width: 15%;">2016 \$'000</th> </tr> </thead> <tbody> <tr> <td>Final Dividend</td> <td></td> <td></td> </tr> <tr> <td>A franked Final Dividend of 2.5 cents (2016: 1.5 cents) per share will be paid on 28 September 2017.</td> <td style="text-align: right;">2,567</td> <td style="text-align: right;">1,535</td> </tr> <tr> <td>Current Year Interim</td> <td></td> <td></td> </tr> <tr> <td>An unfranked Interim Dividend of 1.5 cents (2016: 1.5 cents) per share was paid on 24 March 2017.</td> <td style="text-align: right;">1,540</td> <td style="text-align: right;">1,526</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2017 \$'000	2016 \$'000	Final Dividend			A franked Final Dividend of 2.5 cents (2016: 1.5 cents) per share will be paid on 28 September 2017.	2,567	1,535	Current Year Interim			An unfranked Interim Dividend of 1.5 cents (2016: 1.5 cents) per share was paid on 24 March 2017.	1,540	1,526	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2017 \$'000	2016 \$'000																	
Final Dividend																			
A franked Final Dividend of 2.5 cents (2016: 1.5 cents) per share will be paid on 28 September 2017.	2,567	1,535																	
Current Year Interim																			
An unfranked Interim Dividend of 1.5 cents (2016: 1.5 cents) per share was paid on 24 March 2017.	1,540	1,526																	
No foreign sourced dividend or distribution is included in either the interim or final dividends.																			
7.	<p>Dividend or Distribution reinvestment plans</p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																		
8.	<p>Statement of Retained Earnings</p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																		
9.	<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2017</th> <th style="text-align: right; width: 15%;">2016</th> </tr> </thead> <tbody> <tr> <td>Net Tangible Assets per security</td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;">\$0.23</td> <td style="text-align: right;">\$0.17</td> </tr> </tbody> </table>		2017	2016	Net Tangible Assets per security			Net Tangible Assets per security	\$0.23	\$0.17									
	2017	2016																	
Net Tangible Assets per security																			
Net Tangible Assets per security	\$0.23	\$0.17																	
10.	<p>Details of entities over which control has been gained or lost during the period</p> <p>There are no entities over which control has been gained or lost during the period</p>																		
11.	<p>Associates and joint venture entities</p> <p>There are no associates or joint venture entities</p>																		
12.	<p>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</p> <p>Please refer to section 2.6</p>																		
13.	<p>Foreign Entity accounting standards</p> <p>Australian Accounting Standards & International Financial Reporting Standards</p>																		

14.	<p>Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 8 of the attached Financial Statements.</p> <p>Returns to shareholders including distributions and buy backs. Please refer to Note 9 of the attached Financial Statements.</p> <p>Significant features of operating performance. Please refer to section 2.6.</p> <p>The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.</p> <p>Discussion of trends in performance. Please refer to section 2.6.</p>
15.	<p>Audit Statement</p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The *accounts have been audited. <input type="checkbox"/> The *accounts have been subject to review.</p> <p><input type="checkbox"/> The *accounts are in the process of being audited. <input type="checkbox"/> The *accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 18 August 2017



Print name: Sam Hupert
Chief Executive Officer